Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India; Jawaharlal Nehru University, New Delhi, India.
Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India.
Arch Biochem Biophys. 2024 Jun;756:110022. doi: 10.1016/j.abb.2024.110022. Epub 2024 Apr 30.
Cancer treatment has seen significant advancements with the introduction of Onco-immunotherapies (OIMTs). Although some of these therapies have received approval for use, others are either undergoing testing or are still in the early stages of development. Challenges persist in making immunotherapy widely applicable to cancer treatment. To maximize the benefits of immunotherapy and minimize potential side effects, it's essential to improve response rates across different immunotherapy methods. A promising development in this area is the use of extracellular vesicles (EVs) as novel delivery systems. These small vesicles can effectively deliver immunotherapies, enhancing their effectiveness and reducing harmful side effects. This article discusses the importance of integrating nanomedicines into OIMTs, highlighting the challenges with current anti-OIMT methods. It also explores key considerations for designing nanomedicines tailored for OIMTs, aiming to improve upon existing immunotherapy techniques. Additionally, the article looks into innovative approaches like biomimicry and the use of natural biomaterial-based nanocarriers (NCs). These advancements have the potential to transform the delivery of immunotherapy. Lastly, the article addresses the challenges of moving OIMTs from theory to clinical practice, providing insights into the future of using advanced nanotechnology in cancer treatment.
癌症治疗随着肿瘤免疫疗法（OIMTs）的引入取得了重大进展。虽然其中一些疗法已经获得批准使用，但其他疗法仍在测试中或处于早期开发阶段。在使免疫疗法广泛适用于癌症治疗方面仍然存在挑战。为了最大限度地提高免疫疗法的效益并最小化潜在的副作用，提高不同免疫疗法方法的反应率至关重要。在这一领域，一个有前途的发展是使用细胞外囊泡（EVs）作为新型递药系统。这些小囊泡可以有效地递送免疫疗法，提高其疗效并减少有害的副作用。本文讨论了将纳米医学整合到 OIMTs 中的重要性，强调了当前抗-OIMT 方法的挑战。它还探讨了为 OIMTs 设计纳米医学的关键考虑因素，旨在改进现有的免疫疗法技术。此外，本文还探讨了仿生学和使用基于天然生物材料的纳米载体（NCs）等创新方法。这些进展有可能改变免疫疗法的递药方式。最后，本文探讨了将 OIMTs 从理论转化为临床实践的挑战，为未来在癌症治疗中使用先进的纳米技术提供了见解。
